Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company specializing in the development of innovative oral antiviral therapies to address unmet medical needs. Leveraging their expertise in antiviral drug development, medicinal chemistry, biology, biochemistry, and virology, Atea is focused on discovering and developing novel product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, including serious viral infections such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HCV. Their lead candidate, bemnifosbuvir (AT-527), is an oral direct-acting antiviral currently being evaluated in a global Phase 3 registrational trial for the treatment of COVID-19. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase (nsp12) with a unique mechanism of action, offering dual inhibition of RNA dependent RNA polymerase (RdRp) and nucleotidyltransferase (NiRAN) to potentially create a high barrier to resistance.